Metformin May Be Safer Than Sulfonylureas in Patients With Diabetes and Heart Failure
1st Oct 2005, 19:14 GMT
Metformin, alone or in combination, in subjects with heart failure and type 2 diabetes was associated with lower morbidity and mortality than was sulfonylurea monotherapy. (CME) Medscape Medical News Laurie Barclay,Charles Vega,Gary Vogin
Metformin May Be Safer Than Sulfonylureas in Patients With Diabetes and Heart Failure related news:
- Metformin May Be Safer Than Sulfonylureas in Patients With Diabetes and Heart Failure — Medscape Nursing Headlines
- New benefits in reducing risk of CVD and cancer in diabetics from metformin — OnMedica Latest News
- Drug can reduce risk of death, heart attack, and stroke in patients with diabetes — Medical News Today RSS/XML Feed
- Hospitalized patients with severe congestive heart failure did not experience a benefit from use of pulmonary artery catheterization — News-Medical News Feed
- Use of pulmonary artery catheterization does not show benefit for severe heart failure patients — EurekAlert! - Breaking News
- Evaluation of a Progressive Treatment Program for Erectile Dysfunction in Patients with Diabetes Mellitus — Medscape Diabetes Headlines
- PACs should not be used routinely in patients in intensive care units with severe heart failure — News-Medical News Feed
- Stem Cell Therapy Pioneer, Dr. Amit Patel, Treats More Heart Failure Patients in Bangkok — PR Web (The Free Wire Service) Medical Cardiology
- Lancet publishes proactive study: Diabetes treatment reduces risk of heart attacks & strokes — KeralaNext: Science
- Nocturnal dialysis improves heart disease in patients with end-stage kidney failure — KeralaNext: Science